Open AccessEffect of Alendronate with β – TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial
Author(s) -
Rohini Naineni,
V Ravi,
Dwijendra Kocherlakota Subbaraya,
Jammula Surya Prasanna,
Veerendranath Reddy Panthula,
Rekha Rani Koduganti
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/20965.8365
Subject(s) - medicine , dentistry , dental alveolus , gingival recession , saline , alendronic acid , resorption , bone resorption , bisphosphonate , bleeding on probing , apposition , reduction (mathematics) , osteoporosis , periodontitis , geometry , mathematics
Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for growth factors and antibiotics. Drug delivery vehicles, like β-TCP, improve the potency of the drugs by specific local site delivery of the drug, optimal release characteristics and easy handling.